IPO - REVIVA PHARMACEUTICALS HOLDINGS, INC.

Form Type: 424B5

Filing Date: 2025-05-30

Corporate Action: Ipo

Type: New

Accession Number: 000143774925019011

Filing Summary: Reviva Pharmaceuticals Holdings, Inc. filed a prospectus supplement to offer common stock amounting to up to $50,000,000. The shares will be sold through a sales agreement with B. Riley Securities, Inc. and A.G.P./Alliance Global Partners as agents. The common stock is traded on Nasdaq under the symbol 'RVPH', and the offering is structured as an at-the-market equity offering, meaning the price will fluctuate based on market conditions. The intended use of proceeds includes funding research and development activities and general corporate purposes. The document also outlines the risks associated with investing in the offered securities, emphasizing that the offering price may exceed the net tangible book value per share. The prospectus provides comprehensive details regarding the stock offering, risk factors, and the company's business operations, with a focus on their lead drug candidate brilaroxazine, currently in development for various neuropsychiatric and respiratory indications.